November 18, 2026
Health news, explained with evidence
LIVE

Study Sheds Light on Immune Response and IL-6 Dynamics in Severe Fever with Thrombocytopenia Syndrome

🔬 Research 2 min read 👁 3

A retrospective cohort study published in Nature Health Sciences investigates how interleukin-6 levels and immune cell counts relate to disease severity in patients with severe fever with thrombocytopenia syndrome (SFTS).

🔬Research

Key points

  • Study evaluated 120 SFTS patients across various severity grades
  • Admission IL-6 levels and initial viral load were significantly higher in critical illness
  • Initial viral burden rather than delayed clearance linked to severe outcomes

Researchers at Jeju National University College of Medicine and Hospital have published a retrospective cohort study examining the immune response in patients with severe fever with thrombocytopenia syndrome (SFTS), a tick-borne illness caused by Dabie bandavirus. The study evaluated 120 patients classified across varying degrees of illness severity, ranging from asymptomatic to critical cases.

Key Immune Findings

The analysis revealed that hospital admission levels of interleukin-6 (IL-6)—a key inflammatory marker—rose progressively across severity grades. Specifically, mild cases showed average levels of 9.1 pg/mL, moderate cases 12.6 pg/mL, and severe cases 61.4 pg/mL, with critical patients exhibiting even higher concentrations. Additionally, patients who developed critical illness demonstrated lower initial CD4+ T-cell counts and a reduced one-week CD4/CD8 ratio. Initial viral loads were also notably higher in critical patients, suggesting that the initial viral burden, rather than delayed viral clearance, links more closely to severe outcomes.

What to know: While the findings offer a novel two-axis model for understanding SFTS progression and highlight IL-6 as a potential marker for severe disease, the retrospective nature and specific cohort mean the framework remains hypothesis-generating and requires external validation.

Patients should consult qualified healthcare providers for medical advice, diagnosis, or treatment decisions regarding infectious diseases and individual health concerns.

Source Nature Health Sciences — nature.com/articles/s41598-026-79348-7 ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.